Reference video
A video on the same topic from an external channel, separate from the reports analyzed here.
FDA Committee Recommends Moderna mRNA Flu Vaccine
First new vaccine review since 2023 for adults 50 and over.
Event Overview
An FDA expert advisory committee unanimously recommended the approval of Moderna's first mRNA-based flu vaccine, mFlusiva, for older adults. The recommendation is supported by a 40,000-person study and phase 3 trial results published in the New England Journal of Medicine. The vaccine is noted for the technological advantage of mRNA, which allows for faster manufacture in response to viral mutations.
Issue Summary
Bias Distribution
Bias Signal Summary
Related Coverage
Coverage flow
Coverage volume
Focus shift
Story timeline
Recommended Reads
Key FDA committee unanimously recommends its first vaccine since 2023 - NPR
NPR
New First-of-Its-Kind Flu Vaccine Approved by FDA Expert Panel - ScienceAlert
sciencealert.com
FDA panel backs first-of-its-kind flu vaccine using mRNA technology - AP News
AP News
① The FDA's top vaccine advisory committee unanimously recommended Moderna's mRNA flu vaccine for adults 50 and over, ma
An FDA independent advisory committee unanimously recommended the approval of Moderna's mFlusiva, the first flu vaccine
① No news event was reported as the provided text is a website access error message. ② The outlet does not argue or emph
Loading comments...